SIX · ROP.SW
Roche Holding AG
CHF 401.70+CHF 2.90 (+0.73%)
Roche Holding AG’s quoted price sits in the upper half of its reported 52-week range, 0.67% below the high.
Loading market information…
SIX · ALC.SW · CHF
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 04:30 PM UTC. Cached market data; not a live quote.
One-year closing-price history · CHF. Historical prices are not a forecast.
Alcon Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.02% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Alcon Inc.’s forward annual dividend is CHF 0.28 per share, paid annual. The forward yield is 0.48% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Alcon Inc.’s next earnings report is currently expected on Nov 10, 2026, with estimated earnings per share of CHF 0.70. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Alcon Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Alcon Inc. is a global eye care enterprise dedicated to the research, development, manufacturing, and distribution of a comprehensive range of vision products for both eye care professionals and their patients worldwide. The company operates through two primary divisions. Its Surgical segment equips ophthalmic surgeons with advanced solutions for various procedures. This includes specialized equipment, diagnostic instrumentation, and implantable devices such as intraocular lenses (IOLs), alongside a full suite of consumables like viscoelastic substances, surgical solutions, and customized procedure kits. For cataract interventions, key offerings feature the Centurion Vision System, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA System for intra-operative measurements. Vitreoretinal surgeons benefit from systems like Constellation Vision, procedure packs, lasers, and a variety of specialized micro-instruments, including grieshaber and MIVS tools, scissors, forceps, medical-grade vitreous tamponades, and Hypervit vitrectomy probes. Refractive surgery innovations include WaveLight lasers and Contoura Vision for LASIK treatments, and the segment also provides the EX-PRESS glaucoma filtration device. Its IOL portfolio, prominently featuring AcrySof IQ, includes advanced technology lenses like PanOptix and ReSTOR, designed to correct presbyopia and astigmatism during cataract removal. The Vision Care segment addresses everyday eye health needs. It offers a diverse selection of contact lenses, including daily disposables, reusable options, and color-enhancing varieties. This segment also provides ocular health products for conditions such as dry eye, glaucoma, and allergies, in addition to contact lens care solutions, ocular vitamins, and redness-relieving drops. Prominent brands within this segment include TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux. Founded in 1945, the company was initially known as Alcon Universal S.A. before rebranding as Alcon Inc. in December 2001. Its headquarters are located in Geneva, Switzerland.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:11 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 | May 13, 2025 | CHF 0.58-5.09% vs estimate | CHF 2.11B+3.26% vs estimate |
|---|
| Q4 2024 | Feb 26, 2025 | CHF 0.64+1.59% vs estimate | CHF 2.27B+3.12% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | CHF 0.81+24.62% vs estimate | CHF 2.10B-2.67% vs estimate |
|---|
Latest available per-share figures in CHF. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
23 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CHF 401.70+CHF 2.90 (+0.73%)
Roche Holding AG’s quoted price sits in the upper half of its reported 52-week range, 0.67% below the high.
€178.20+€0.50 (+0.28%)
EssilorLuxottica S.A.’s quoted price sits in the lower half of its reported 52-week range, 44.97% below the high.
¥25,875-¥455 (-1.73%)
HOYA Corporation’s quoted price sits in the lower half of its reported 52-week range, 14.88% below the high.
$242.48+$61.05 (+33.65%)
Glaukos Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.51% below the high.
$60.34+$0.93 (+1.57%)
The Cooper Companies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 32.83% below the high.
CA$28.75+CA$0.19 (+0.67%)
Bausch + Lomb Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.3% below the high.
$25.24+$0.63 (+2.56%)
STAAR Surgical Company’s quoted price sits in the lower half of its reported 52-week range, 29.63% below the high.
$9.57+$0.33 (+3.57%)
Sight Sciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.47% below the high.
